• Merck (NYSE:MRK) faces an upcoming Gardasil vaccine safety trial scheduled for late July, focusing on product safety and potential liability claims.
• The company has also published new research on a large scale, enzyme enabled synthesis route for its oral PCSK9 inhibitor candidate.
• This synthesis work could help support development of what may become one of the first oral PCSK9 treatments for cholesterol management.

Merck enters these developments with its stock at $112.3 and a return of 49.9% over the past year, alongside a 75.2% return over the past 5 years. Over the shorter term, NYSE:MRK shows a 2.9% return over the past week and a 5.5% return year to date, while the past month reflects a 5.9% decline.

For investors, the late July Gardasil trial centers on legal and reputation risk. The oral PCSK9 synthesis work highlights progress in Merck's pipeline. The evolution of these developments could influence sentiment around the stock's risk profile and its role in cholesterol treatment research.

Stay updated on the most important news stories for Merck by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Merck.

The Gardasil safety trial and the oral PCSK9 synthesis work pull Merck in two different directions for investors. On one side, the July 27 trial introduces legal and reputation risk around an established vaccine at a time when regulators and payers are already closely watching vaccine safety and pricing. On the other, publication of an enzyme enabled route to manufacture an oral PCSK9 candidate speaks to Merck’s efforts in cardiometabolic drugs, an area where it competes with Pfizer, Novartis and Amgen. The synthesis route is important because complex macrocyclic peptides can be costly and hard to scale, so a more efficient process can matter for future margins and access if the drug progresses.

How This Fits Into The Merck Narrative

• The oral PCSK9 work aligns with the narrative that Merck is broadening growth drivers in cardiometabolic and other areas to reduce reliance on KEYTRUDA and GARDASIL over time.
• The Gardasil trial highlights a risk that the narrative already flags around vaccine policy and demand, and it could intensify concerns if the outcome leads to tighter scrutiny or higher liability costs.
• The specific manufacturing angle of the PCSK9 synthesis, including potential cost and scalability benefits, is not fully reflected in the narrative’s high level view of the pipeline.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Merck to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ The upcoming Gardasil trial could increase legal expenses and keep vaccine safety concerns in focus if additional cases follow.
• ⚠️ Analysts already flag five minor risks including margin pressure and debt, and any extra spending on litigation or manufacturing scale up could add to those pressures.
• 🎁 Progress on an oral PCSK9 candidate gives Merck another potential cardiometabolic asset alongside injectables from competitors, which may help diversify future revenue streams.
• 🎁 An efficient, enzyme based synthesis route for complex peptides could support more scalable production if the drug advances, which may support economics if pricing pressure intensifies across big pharma peers.

What To Watch Going Forward

From here, focus on three things. First, the outcome and legal commentary around the July Gardasil trial and whether it prompts further cases or regulatory reactions. Second, any updates on clinical progress, partnerships or timelines for the oral PCSK9 program, including how Merck positions it against existing cholesterol treatments. Third, how management addresses these items in future guidance, given Merck recently updated 2026 sales guidance and carries ongoing R&D and acquisition related charges. Together, these elements will shape how investors think about Merck’s risk profile and its efforts to balance vaccine, oncology and cardiometabolic exposure.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Merck, head to the community page for Merck to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.